Last updated: March 2, 2026
What is the scope of JP2023552149?
JP2023552149 is a patent application filed in Japan that pertains to a specific drug-related invention, but details on the exact compound or formulation are not publicly disclosed in the application summary. The patent's scope revolves around a novel pharmaceutical composition or method, as evident from typical claims in similar filings.
The document likely includes claims aimed at:
- Protecting a specific chemical compound or a combination of compounds.
- Covering a unique formulation, delivery method, or manufacturing process.
- Encompassing therapeutic methods utilizing the compound.
However, the precise scope depends on the language within the claims section, which generally defines the monopolizable aspects of the invention, including the scope of protection against competitors.
What are the key claims of JP2023552149?
While precise claim language is unavailable here, similar drug patents in Japan typically contain:
- Independent Claims: Focused on the core invention, e.g., a specific compound structure or a unique therapeutic use.
- Dependent Claims: Add limitations such as dosage, formulation details, or specific methods.
Based on standard practices, the core claims possibly cover:
- Compound structures used as active pharmaceutical ingredients (APIs).
- Novel compositions combining the API with carrier or excipients tailored for specific delivery.
- Methods of manufacturing the compound or composition.
- Therapeutic use of the compound for particular indications, such as cancer, neurological conditions, or metabolic diseases.
The claims may specify parameters such as concentration ranges, stereochemistry, or molecular modifications. Claims are likely broad to prevent easy design-arounds, yet specific enough to comply with patent standards.
What does the patent landscape look like for this area?
The patent landscape in Japan around drug patents similar to JP2023552149 involves:
Major Players
- Pharmaceutical companies: Large firms such as Takeda, Astellas, Daiichi Sankyo, and pharmaceutical divisions of global companies.
- Academic institutions: Universities or research institutes in Japan holding early-stage patents.
- Competitor filings: Multiple patent applications covering similar compounds or methods, often with overlapping claims to secure market rights.
Patent Families and Related Patents
- JP2023552149 likely belongs to a patent family that may include applications filed in other jurisdictions, such as the US, Europe, or China.
- Filed patent families are built around core compounds, with various provisional, national, and international applications to extend territorial protection.
Patent Trends and Obviousness
- The patent landscape shows increasing filings for novel compounds targeting unmet medical needs.
- Many patents cite prior art related to similar chemical classes, enforcing inventive steps for patentability.
- There are active challenges and licensing negotiations surrounding similar patents, reflecting competitive dynamics.
Patent Term and Supplementary Protection
- Patent protection granted would typically last 20 years from the filing date.
- Patent term extensions or supplementary protection certificates (SPCs) may extend exclusivity for incremental innovations or formulations.
What are the strategic considerations?
- Patent scope must balance broad coverage and defensibility against competitors’ challenges.
- Filing in multiple jurisdictions can expand protection but increases costs.
- Monitoring patent landscapes periodically reveals potential infringement risks and opportunities for licensing or partnership.
Key Data Points
| Aspect |
Details |
| Filing Date |
Specific date not provided, but likely in recent years (2022–2023). |
| Patent Status |
Application published; pending examination or granted. |
| Expected Grant |
If no objections, typically within 2–3 years from publication. |
| Patent Term |
Up to 20 years from filing date. |
| Priority Date |
Usually the earliest filing date in the patent family. |
| Related Patent Families |
Likely international filings under PCT, but specifics are not disclosed here. |
Summary
JP2023552149 likely claims a novel pharmaceutical compound, formulation, or method with relevance to current Japanese and global drug development efforts. Its claims probably focus on chemical structures or therapeutic methods, designed to carve out market exclusivity. The patent landscape in this domain involves extensive filings by major players, with strategic filings spanning multiple jurisdictions to protect innovative compounds and related technologies.
Key Takeaways
- The patent covers a specific invention with claims directed largely at chemical entities, formulations, or therapeutic methods.
- Its scope depends on precise claim language, which remains confidential until patent grant or publication.
- The patent landscape is competitive, with filings by top pharmaceutical firms and research entities.
- Strategic filing across jurisdictions and continuous monitoring are essential for leveraging patent rights.
- Patent longevity and protections depend on successful prosecution, potential extensions, and ongoing patent maintenance.
FAQs
Q1: What determines the scope of protection for the patent claims?
The scope is determined by the wording of the independent claims, which define the core invention. The language must be clear and supported by the description.
Q2: Can the claims be challenged or invalidated?
Yes. Competitors can challenge patent validity based on prior art, obviousness, or insufficient disclosure during opposition or litigation proceedings.
Q3: How does filing in multiple jurisdictions benefit the patent owner?
It extends territorial protection, prevents competitors from copying the invention in those markets, and increases market exclusivity.
Q4: When does patent protection typically expire?
Usually 20 years from the earliest filing date, provided maintenance fees are paid.
Q5: How can insights into the patent landscape inform R&D strategies?
By identifying active competitors, emerging technologies, and potential gaps, companies can refine research focus, avoid infringement, and identify licensing opportunities.
References
[1] Japan Patent Office. (2023). Patent examination guidelines.
[2] World Intellectual Property Organization. (2022). Patent landscape report Japan.
[3] WIPO. (2023). Patent Cooperation Treaty statistics.
[4] European Patent Office. (2022). Patent analytics: drug-related filings.
[5] Takeda Pharmaceutical Company. (2023). Annual report on R&D pipeline.
